Implantable Loop Recorder (Reveal LINQ): How It Works, What the Evidence Shows

2. What It Is

An implantable loop recorder (ILR) is a small subcutaneous cardiac monitor implanted under the skin of the left chest. It records a single-channel subcutaneous ECG continuously, stores episodes meeting programmable detection criteria, and transmits data remotely.

Two major FDA-cleared systems are currently in clinical use:

Medtronic Reveal LINQ: The current generation LINQ device is 1.2 mL in volume, approximately the size of a AAA battery. It is inserted via a minimally invasive procedure using an insertion tool (similar to a large-gauge introducer) through a small skin incision under local anesthesia, without sutures in most cases. The LINQ IQ (latest generation) has a battery life of up to 4.5 years. It communicates wirelessly with a home transmitter (the MyCareLink Smart monitor) that automatically transmits stored data to Medtronic’s CareLink network nightly when the transmitter is within range of the patient.

Abbott Confirm Rx: The Confirm Rx is a similar size (1.2 cc). It uses Bluetooth Low Energy to communicate directly with the patient’s smartphone (no separate home transmitter required), enabling real-time transmission. The patient can also manually transmit a recording when they feel symptoms by activating the MyMerlin app. Battery life approximately 2 years.

Regulatory status: Both devices are FDA-approved as Class III devices under Premarket Approval (PMA). The Reveal LINQ PMA was approved in 2014 (P130031 and supplements). The Confirm Rx received De Novo clearance and subsequent PMA supplements. Both carry CE marking in Europe. These are implantable devices with significant clinical evidence bases.

Cost: The ILR procedure is typically covered by Medicare and most commercial insurance for approved indications (unexplained syncope after non-diagnostic workup, cryptogenic stroke for AF detection, AF monitoring in documented paroxysmal AF). The device cost is approximately $1,000-$1,500; total procedure cost including professional fees is $3,000-$5,000. For cryptogenic stroke specifically, the cost-effectiveness ratio is highly favorable given the cost of a second stroke.

3. The Mechanism

3.1 Subcutaneous ECG Recording

The ILR implanted in the left chest records the electrical potential difference between the device’s two sensing electrodes across the chest wall. This is a single-vector subcutaneous ECG, not equivalent to any standard 12-lead position but providing a signal capable of reliable R-wave detection and rhythm characterization.

The signal quality of a subcutaneous ECG differs from surface ECG:

• R-wave amplitude is typically lower than in surface leads
• P-waves may be small or invisible in many patients (the subcutaneous vector does not at target align with the atrial depolarization direction in many anatomical positions)
• T-wave morphology can be altered
• Skeletal muscle artifact from arm movement produces baseline noise

Despite these differences, the subcutaneous ECG is sufficient for:

• Reliable AF detection (irregular R-R intervals with absent organized P-waves)
• Pause detection (long intervals without R-wave)
• VT/VF detection (fast broad-complex rhythm)
• SVT detection (fast narrow-complex rhythm)

It is not sufficient for:

• P-wave morphology characterization (atrial flutter, focal AT identification)
• QRS morphology discrimination (LBBB vs RBBB vs RVOT VT)
• ST-segment monitoring (ischemia detection)

3.2 Auto-Detection Algorithms

The LINQ and Confirm Rx use proprietary algorithms that classify stored electrograms into categories:

• AF/AFL: Irregularly irregular R-R intervals with absence of organized atrial activity. AF detection sensitivity exceeds 95% in validation studies; specificity above 90% 5 / Solid .

• Pause: R-R interval exceeding programmable threshold (typically 3.0-5.0 seconds). Stored for physician review.

• Bradycardia: Sustained rate below programmable lower rate threshold.

• Tachycardia: Sustained rate above programmable upper rate threshold.

• Patient-activated episode: The patient can activate episode storage by holding a small handheld activator over the device or using a smartphone app (Confirm Rx via Bluetooth).

False detections are a known limitation of ILR auto-detection. T-wave oversensing (counting a T-wave as a QRS, producing apparent rate doubling) can trigger inappropriate tachycardia storage. R-wave undersensing (missing QRS complexes) can produce apparent pauses. Physician review of all stored electrograms is required; the algorithm output is not clinically accepted without electrogram verification.

3.3 Remote Monitoring Architecture

The home transmitter (LINQ) or smartphone app (Confirm Rx) automatically transmits stored episodes to the manufacturer’s remote monitoring network (CareLink for Medtronic; Merlin.net for Abbott) nightly. The clinic receives a notification when significant findings are transmitted.

Remote monitoring means that a significant arrhythmia detected at 4 AM on a farm in rural Arthur, Illinois, can be reviewed by a cardiologist in Urbana by 8 AM the same morning. This is the geographic equity contribution of remote monitoring: the patient does not need to be physically present in the cardiology clinic for their monitoring data to reach their physician.

The clinic must have a workflow for reviewing remote monitoring transmissions. Clinics that subscribe to CareLink or Merlin.net receive daily transmission summaries. High-priority alerts (AF episode, significant pause, VT detection) generate immediate alert notifications to the clinic. The clinical coordinator who receives the alert must have a clear protocol: who reviews electrograms, who calls the patient, what threshold triggers same-day evaluation vs next-day call vs scheduled follow-up.

4. How It Is Used

4.1 Cryptogenic Stroke and AF Detection

This is the indication with the strongest evidence base. Cryptogenic stroke accounts for 25-30% of all ischemic strokes. The most common undetected cause: paroxysmal AF with AF-related cardioembolic stroke.

The standard evaluation for cryptogenic stroke (carotid imaging, cardiac imaging, standard ECG, 24-hour Holter) detects AF in approximately 4-7% of patients. Extended external monitoring (30-day) detects AF in an additional 10-15%. The ILR detects AF in an additional 15-20% over 3 years, cumulative detection rate of approximately 30% at 3 years.

The clinical implication: for every three patients with cryptogenic stroke who receive an ILR and are monitored for 3 years, approximately one will have AF detected that changes their anticoagulation strategy. 5 / Solid

4.2 Unexplained Syncope

For syncope with suspected arrhythmic mechanism where external monitoring is non-diagnostic, the ILR provides continuous monitoring for up to 3-4 years. The ISSUE series of studies established ILR-guided syncope management:

ISSUE-2 (Brignole 2006): ILR implanted in 392 patients with recurrent unexplained syncope. AF, bradycardia, or asystole detected in 29% at 1 year. Treatment based on electrogram findings reduced recurrence significantly 5 / Solid .

ISSUE-3 (Brignole 2012): Patients with ILR-confirmed asystolic syncope randomized to pacemaker vs no pacemaker. Pacemaker implantation reduced syncope recurrence by 57% (HR 0.43, 95% CI 0.23-0.80). 5 / Solid

The ISSUE-3 result is the most direct evidence that ILR-guided therapy (implanting a pacemaker only in patients confirmed to have asystolic syncope by ILR) improves outcomes. It validates the ILR not just as a diagnostic tool but as the foundation of a treatment decision.

4.3 Known AF Management

In patients with known AF, the ILR enables:

• AF burden quantification: How much time is the patient spending in AF? Is the rhythm control strategy working? The LINQ provides a continuous AF burden estimate, more accurate and granular than any external monitoring tool.

• AF recurrence detection after ablation: Post-ablation AF recurrence is common and often asymptomatic. ILR monitoring after ablation enables accurate efficacy assessment and early identification of recurrence.

• Anticoagulation optimization: For patients with low to moderate AF burden, ILR data informs whether continuous anticoagulation or shorter anticoagulation courses are appropriate (an emerging clinical question not yet fully answered by RCTs; guidelines still recommend anticoagulation based on CHA2DS2-VASc regardless of AF burden, but this is under ongoing investigation).

4.4 REVEAL AF Study

Design: Prospective, single-arm, multicenter study. 385 patients with CHA2DS2-VASc score ≥3 and no known AF. ILR implanted. Follow-up 18 months.

Results: AF detected in 40.0% of patients at 18 months, 29.7% with AF episodes >1 hour. Median time to AF detection: 123 days. Anticoagulation initiated in 91% of AF-detected patients.

Interpretation: In patients with raised stroke risk but no prior AF diagnosis, ILR-based AF screening detects AF in a substantial minority and leads to treatment changes. 4 / Promising

5. The Evidence

5.1 CRYSTAL AF Trial (Sanna 2014, NEJM)

This is the landmark trial for ILR in cryptogenic stroke.

Design: 441 patients with recent cryptogenic stroke, randomized to ILR (Reveal XT or later) vs standard monitoring (clinical assessment per investigator judgment).

Primary outcome: Time to first AF detection at 6 months.

Results:

• AF detected at 6 months: 8.9% ILR group vs 1.4% standard monitoring (HR 6.4, 95% CI 2.7-15.5)
• AF detected at 12 months: 12.4% vs 2.0%
• AF detected at 36 months: 30.0% vs 3.0%

ILR detected 10 times more AF at 3 years compared to standard monitoring. 5 / Solid

Clinical impact: Patients in the ILR group with detected AF were anticoagulated. Whether this anticoagulation prevented secondary strokes was not the primary endpoint, but this is the expected clinical mechanism of benefit.

5.2 EMBRACE Trial (Gladstone 2014, NEJM)

Design: 572 patients with recent cryptogenic TIA or stroke randomized to 30-day event monitor vs standard ECG monitoring (24-hour Holter).

Results: AF detected in 16.1% vs 3.2% (absolute difference 12.9%, 95% CI 8.0-17.6). More patients in the 30-day monitor group received anticoagulation.

Relevance to ILR: EMBRACE establishes that 30-day external monitoring is a reasonable step before ILR for cryptogenic stroke. CRYSTAL AF and EMBRACE together define the monitoring strategy: start with 30-day extended monitoring; if negative, proceed to ILR for patients who remain without identified cause. 5 / Solid

5.3 CRYSTAL AF vs EMBRACE: Complementary Findings

EMBRACE showed 30-day external monitoring is better than 24-hour Holter. CRYSTAL AF showed 3-year ILR is better than standard monitoring. The combined inference:

1. Standard monitoring (ECG + Holter): detects 3-7% AF in cryptogenic stroke
2. 30-day external monitoring: detects an additional 10-15%
3. ILR at 3 years: detects an additional 15-20% on top of external monitoring

For a patient at high clinical probability for occult AF (older, hypertensive, with left atrial enlargement on echocardiogram, with cryptogenic stroke), proceeding directly to ILR after a negative 30-day external monitor is supported by the evidence.

5.4 AF Detection Comparison Table

5.5 ISSUE Series for Syncope

See Section 4.2 above. The ISSUE-3 trial is the strongest evidence for ILR-guided syncope management 5 / Solid .

5.6 ILR False Detections and Clinical Burden

A known limitation of current ILR systems: automated AF detection generates false-positive detections in approximately 10-15% of detected AF episodes in real-world practice. The predominant false-positive mechanism is T-wave oversensing, which produces apparent rate doubling and an irregular-appearing rhythm that mimics AF on the stored electrogram.

Physicians who interpret ILR electrograms must verify AF by assessing:

• Absence of organized P-wave or flutter pattern
• Truly irregular R-R intervals (not a doubling artifact)
• Duration consistent with clinical significance

The clinical consequence of false-positive AF detection is unnecessary anticoagulation. In an older patient with high bleeding risk, this is not a trivial harm. Careful electrogram interpretation is required; the algorithm’s output is a hypothesis, not a diagnosis.

6. The Patient Experience

6.1 The Implantation Procedure

ILR implantation takes approximately 5-10 minutes in an ambulatory setting. The patient receives local anesthetic (lidocaine injection) at the implant site, typically in the left parasternal area below the clavicle. A small incision (approximately 0.5-1 cm) is made in the skin. The insertion tool (pre-loaded with the device) is introduced into the subcutaneous tissue and the device is deployed and the tool withdrawn. The incision is closed with Steri-Strips or a small suture.

The patient experiences:

• Local anesthetic injection (brief sting)
• Pressure sensation during insertion (not painful with adequate local anesthetic)
• Small skin closure at the site
• 15-30 minutes of post-procedure monitoring
• Discharge home same day

Post-procedure: the site is tender for 3-7 days. Patients are instructed to keep the incision dry for 48 hours and to avoid heavy lifting with the left arm for one week. Most patients return to normal activity within 2-3 days.

The device is not visible on the skin in most patients unless the patient is very thin. It is not palpable as a bump in most positions. Patients occasionally report being able to feel the device edge when pressing on the site directly.

6.2 Living with the ILR

For most patients, the ILR is functionally invisible. There is nothing to do daily: the device monitors continuously and transmits automatically. The home transmitter (LINQ) must be plugged in and placed within 6 meters of the patient during sleep for nightly transmission. The Confirm Rx uses Bluetooth to the patient’s smartphone for transmission.

Patients should inform healthcare providers of the ILR before MRI procedures. Both LINQ and Confirm Rx are MRI-conditional (not unconditionally MRI-safe): they can be scanned under specific conditions (1.5T or 3T, specific scanning parameters) as detailed in the device documentation. The ILR MRI labeling should be communicated to any radiology team that performs an MRI.

Airport and building security screening (standard metal detectors) may produce a beep from the ILR’s metallic housing. The device carries no risk from standard security wands. Patients should carry their device identification card.

6.3 Remote Monitoring Follow-Up

ILR follow-up is primarily remote. After the initial post-implant visit (typically 6-8 weeks after implantation), the cardiologist reviews monthly or quarterly remote monitoring transmissions. An in-person visit is scheduled when a significant finding is detected or annually per institutional protocol.

This remote monitoring model is particularly valuable for patients in rural settings. Margaret in Arthur, Illinois, does not need to drive 30 miles to Champaign every month for a device check. Her LINQ transmits data nightly. Her cardiologist reviews the summary. She receives a phone call if anything significant is found. The annual in-person device check is the only required in-person contact.

7. Decisions and Trade-Offs

7.1 When the ILR is the Appropriate Next Step

After non-diagnostic workup for:

• Cryptogenic stroke or TIA (standard monitoring negative or after 30-day external monitor negative)
• Unexplained syncope (episodic, suspected arrhythmic, structural heart disease excluded or present but external monitoring negative)
• Recurrent unexplained palpitations not captured by Holter, 14-day patch, or 30-day event monitor

In selected patients without symptoms:

• High-risk AF surveillance (CHA2DS2-VASc ≥3, no identified AF, as in REVEAL AF)

7.2 The Device Selection: LINQ vs Confirm Rx

Neither device has been shown superior in clinical outcomes. The choice depends on institutional familiarity, patient factors, and technical preference:

LINQ (Medtronic):

• Longer battery life (up to 4.5 years)
• Home transmitter required (passive overnight transmission)
• Established track record in CRYSTAL AF and major clinical trials
• Compatible with the CareLink remote monitoring network

Confirm Rx (Abbott):

• Bluetooth smartphone transmission (no separate home transmitter)
• Patient-activated recording via smartphone
• Shorter battery life (~2 years)
• Compatible with Merlin.net remote monitoring

For patients who are technologically comfortable with smartphones and prefer not to have an additional home device: Confirm Rx may be preferred. For patients who are elderly or less comfortable with smartphones, or who need a longer battery life: LINQ may be preferred.

7.3 The ILR vs External Monitoring Cost Analysis

The ILR is more expensive upfront ($3,000-$5,000 total procedure cost) than a 14-day Zio Patch ($300-$450) or 30-day MCOT ($800-$1,200). For cryptogenic stroke evaluation, cost-effectiveness analyses favor the ILR over repeated external monitoring cycles when the pre-test probability of AF is moderate to high:

A single ILR at 3-year follow-up provides more AF detection than multiple external monitoring cycles while avoiding the logistical burden of repeated monitoring episodes. 4 / Promising

For patients with very low pre-test probability of AF (young patient with cryptogenic stroke, low vascular risk, no left atrial enlargement), external monitoring with 30-day MCOT is a reasonable initial step before committing to ILR implantation.

7.4 What the ILR Cannot Do

The ILR is a rhythm monitor, not a structural monitor. It cannot measure left ventricular ejection fraction, detect valve disease, identify coronary artery stenosis, or assess blood pressure. A negative ILR after 3 years of monitoring means no significant arrhythmia was detected; it does not exclude structural or vascular causes of stroke.

For the patient with cryptogenic stroke and a 3-year negative ILR: the search for embolic source must continue. Aortic arch atherosclerosis, patent foramen ovale (if not previously excluded), hypercoagulable state, and malignancy-associated thromboembolism are considerations that the ILR cannot address.

8. The SDE Synthesis

Margaret’s 19-hour episode of AF, detected at 4:22 AM on a Thursday, eight months after ILR implantation, was clinically silent. She did not feel it. She did not know it was happening. Without the ILR, she would have continued in her current anticoagulation strategy (warfarin for prior DVT, not specifically titrated for AF stroke prevention) without the formal AF diagnosis that would have triggered a conversation about stroke risk, rhythm control, and treatment optimization.

The ILR is the most powerful single tool in the SDE detection framework for the gap between physiological disease and clinical recognition. A 14-day patch closes a 2-week window. An ILR closes a 3-year window. The events it finds are not trivial: 30% of cryptogenic stroke patients have AF detected by ILR at 3 years. That is 30% of patients whose stroke mechanism was unknown and who were therefore not receiving target secondary prevention.

The Stop Dying Early framework is built on the principle that preventable events are prevented by detecting their causes before the second event. For atrial fibrillation as a stroke mechanism, the second event is the devastating stroke that follows the first, smaller stroke or TIA. The ILR intercepts that pathway.

In rural Illinois, where many patients with cryptogenic stroke cannot access frequent urban cardiology follow-up, the ILR’s remote monitoring capability enables continuous surveillance from any geography. A patient in Arthur or in Mount Carroll or in Carmi can transmit data to an academic cardiology center 100 miles away every night without leaving home.

That geographic equity is not an abstraction. For Margaret, it was the difference between a second stroke and a phone call at 8 AM.

SDE Offer Routing:

• SDE Audit (Tier 1): ILR recommendation as part of cryptogenic stroke evaluation and high-risk AF detection workup
• SDE Cohort (Tier 2): ILR remote monitoring integration into quarterly clinical review for patients with known paroxysmal AF, post-ablation AF monitoring, or unexplained syncope
• SDE Snapshot (rapid evaluation): Expedited ILR consultation for patients with recent cryptogenic stroke and completed external monitoring

Sex Differences in ILR Use, Cryptogenic Stroke, and AF Detection

9.1 Sex Differences in Cryptogenic Stroke

Cryptogenic stroke accounts for approximately 25-30% of all ischemic strokes, and women make up the majority of cryptogenic stroke patients in most registries. The CRYSTAL AF trial enrolled 441 patients of whom 38% were female; the EMBRACE trial enrolled approximately 40% women. These are not perfect sex-balanced samples, but they do include enough women to allow the conclusion that the benefit of ILR monitoring after cryptogenic stroke is present in both sexes 5 / Solid .

The reason cryptogenic stroke disproportionately affects women is partially attributable to a higher rate of patent foramen ovale (PFO)-related paradoxical embolism in younger women (particularly women with migraine with aura) and to the higher stroke rate associated with AF in women at equivalent CHA2DS2-VASc scores. A woman with cryptogenic stroke who has a CHA2DS2-VASc score of 5 (which includes the female sex modifier of 1 point, age, hypertension, and prior stroke) has a very high post-stroke stroke recurrence risk that argues strongly for ILR implantation to detect occult AF and initiate anticoagulation.

9.2 Hormonal Influences on AF Detection Timing

In pre-menopausal women with cryptogenic stroke who undergo ILR implantation, the timing of AF detection may correlate with the menstrual cycle. Hormonal fluctuation influences autonomic tone and atrial electrophysiology; the luteal phase is associated with higher sympathetic tone and potentially higher AF susceptibility 3 / Early 01759-X). This is a theoretical consideration for cycle tracking in women with ILR monitoring, but no published trial has correlated ILR-detected AF episodes with menstrual cycle timing in a prospective design. The clinical implication, if any, remains speculative 2 / Theoretical .

9.3 Sex Differences in ILR Implantation Complications

Subcutaneous ILR implantation has a low complication rate (hematoma 1-2%, infection less than 1%, device migration less than 1%). Published registries do not demonstrate significant sex differences in complication rates for ILR implantation 4 / Promising . Women have slightly thinner subcutaneous tissue at the standard left parasternal implant site, which can occasionally create a more visible device contour under the skin. This is a cosmetic consideration, not a clinical complication, but should be mentioned during patient counseling.

Technical Notes on the Reveal LINQ and Confirm Rx

10.1 Reveal LINQ Architecture

The Medtronic Reveal LINQ (approved under PMA P130021) is approximately the size of a USB flash drive (4.4 mL volume, 9 × 45 mm) and is delivered via a dedicated insertion tool that creates a subcutaneous pocket with a single 1-cm incision. The battery life is approximately 3 years. The LINQ communicates with a bedside transmitter (MyCareLink) that uploads data nightly to the Medtronic Carelink network, allowing the patient’s cardiologist to review rhythm data remotely without scheduled device interrogations.

The sensing configuration is a single subcutaneous near-field ECG vector. The electrode-to-electrode distance is the length of the device itself, generating a signal of typically 0.3-1.0 mV, smaller than a surface ECG lead but sufficient for rhythm analysis. The sensing axis (left parasternal subcutaneous) provides good visibility of P waves in most patients and adequate QRS detection for rate counting and irregular rhythm classification.

Automatic detection algorithms run continuously on the device. The sensing parameters are programmable by the implanting physician:

• AF detection: automatic, triggered when RR interval variability exceeds a defined threshold (irregular R-R without P-wave detection)
• Bradycardia detection: configurable pause threshold (default: pause greater than 3 seconds triggers storage)
• Tachycardia detection: configurable rate threshold (default: greater than 180 bpm triggers storage)
• Patient-activated storage: patient presses a small magnet against the skin over the device to trigger a 2-minute pre-event + 2-minute post-event ECG storage

The device stores ECG data for the highest-priority events detected over the previous storage period. Lower-priority events may be overwritten as new events are detected, which means that in a patient with many frequent ectopic beats, the most clinically significant longer-duration events are preferentially retained.

10.2 Confirm Rx Architecture

The Abbott Confirm Rx (approved under PMA P170042) has the same basic architecture as the Reveal LINQ with two significant differences: it is the first ILR to transmit data via Bluetooth to a paired smartphone (the myMerlin patient app), and its battery life is approximately 2 years. The smartphone acts as the transmitter, uploading data from the device app to the Abbott Merlin.net physician portal.

The Bluetooth transmission model has practical advantages: the patient does not need a bedside transmitter module and can carry the transmission capability on their phone wherever they travel. For patients in rural Illinois who spend time away from home or who work in locations where a bedside transmitter cannot be placed, the Confirm Rx’s phone-based transmission eliminates the geographic constraint on daily data upload.

The limitation: the patient must have a compatible iOS or Android smartphone and must carry the phone within approximately 3 feet of their chest during sleep for reliable nightly transmission. Patients who do not own a smartphone or who use incompatible models cannot use the Bluetooth transmission pathway and would require a standard bedside transmitter accessory, which reduces the value of the phone-based design.

10.3 AF Detection Sensitivity and False Positives

Both the LINQ and Confirm Rx detect AF with a sensitivity of approximately 95-98% for sustained AF episodes lasting 2 minutes or longer 5 / Solid . The false positive rate is more variable: in patients with frequent ectopy (PVCs, PACs), high-burden irregular rhythms may be classified as AF when they are actually ectopy-induced RR variation in sinus rhythm. The clinical implication: when an ILR report shows “AF detected,” the cardiologist should review the actual stored ECG trace before initiating anticoagulation or changing management. A 2-minute trace showing irregular RR intervals with identifiable sinus P waves and occasional ectopic beats is not AF; it is sinus rhythm with ectopy. Initiating anticoagulation on the basis of an unreviewed “AF detected” notification is a clinical error with real bleeding risk.

The LINQ and Confirm Rx both store actual ECG data alongside the automatic event classification, allowing the physician to review the rhythm that triggered the detection. This is a mandatory step before clinical decision-making on any ILR-transmitted event.

Evidence Depth — CRYSTAL AF, EMBRACE, and the Post-Stroke ILR Standard

11.1 CRYSTAL AF in Detail

CRYSTAL AF (Sanna T, et al., NEJM 2014; DOI: 10.1056/NEJMoa1313600) enrolled 441 patients with recent cryptogenic stroke or TIA (within 90 days) and no AF on prior monitoring (at least 24 hours of monitoring). Patients were randomized 1:1 to ILR implantation (Reveal XT, the predecessor to the LINQ) versus conventional follow-up (Holter and event monitoring per physician discretion). The primary endpoint was AF detection at 6 months.

Results: At 6 months, AF was detected in 8.9% of ILR patients vs 1.4% of conventional monitoring patients (HR 6.4, p < 0.001). At 12 months, 12.4% vs 2.0% (HR 7.3). At 36 months, 30.0% vs 3.0% 5 / Solid . The absolute difference at 3 years was 27 percentage points. Of the AF-positive patients in the ILR group, 80% received anticoagulation therapy.

What CRYSTAL AF did not show: whether the initiation of anticoagulation in the ILR-detected AF group reduced subsequent stroke recurrence. This is the critical gap. The trial established that ILR detects far more AF than conventional monitoring after cryptogenic stroke; it did not prove that detecting and treating this AF prevents the next stroke. The STROKE AF trial (Bernstein RA, et al., JAMA 2021; DOI: 10.1001/jama.2020.16634) and the LOOP study provide complementary context, but neither definitively closes this evidence gap.

11.2 EMBRACE in Detail

EMBRACE (Gladstone DJ, et al., NEJM 2014; DOI: 10.1056/NEJMoa1407610) compared 30-day event monitoring to 24-hour Holter in 572 patients with recent cryptogenic stroke. AF detection at 90 days was 16.1% in the 30-day monitoring group vs 3.2% in the 24-hour Holter group (relative increase 5.0-fold, p < 0.001) 5 / Solid . EMBRACE confirmed the CRYSTAL AF finding from a different approach: prolonged monitoring detects far more AF than short monitoring, regardless of whether the prolonged monitoring is external (EMBRACE) or implantable (CRYSTAL AF).

The clinical message from EMBRACE and CRYSTAL AF combined: after cryptogenic stroke, 24-hour Holter monitoring is insufficient. External 30-day monitoring should be the minimum standard. ILR monitoring is appropriate when 30-day external monitoring is negative and the clinical suspicion for paroxysmal AF remains high.

11.3 The Stroke AF Trial and the Broader AF-Cause Debate

STROKE AF (Bernstein RA, et al., JAMA 2021; DOI: 10.1001/jama.2020.16634) randomized 492 patients with recent ischemic stroke (not restricted to cryptogenic; included strokes with identifiable non-AF causes) to ILR monitoring vs conventional care. At 12 months, AF detection was 12.1% vs 1.8% (HR 7.4, p < 0.001) 5 / Solid . Even in strokes with apparent non-cryptogenic causes (small vessel disease, moderate atherosclerosis), ILR monitoring detected substantial rates of occult AF.

This finding raises a conceptual challenge: if AF is detected after a stroke that appeared to have a different mechanism, is the AF the cause of the original stroke or a coincidental finding? The STROKE AF investigators argued that in a patient with ESUS (embolic stroke of undetermined source) classification, which encompasses a large fraction of all cryptogenic and non-cryptogenic strokes, AF detection should trigger anticoagulation because the embolic source may have been the AF even if the imaging suggested small-vessel disease. This is currently an area of active debate and clinical guideline development; the answer will likely come from trials comparing anticoagulation versus antiplatelet therapy in ESUS patients with ILR-detected AF.

Illinois-Specific Practice and SDE Integration

12.1 ILR Implantation in the Carle and OSF Networks

ILR implantation is performed in an outpatient or same-day procedure setting, typically in an electrophysiology lab or cardiac catheterization suite under local anesthesia. The procedure takes approximately 20 minutes. At Carle Foundation Hospital in Urbana, ILR implantation is performed in the cardiac EP lab with next-day home discharge. OSF HealthCare in Peoria offers the same service.

For rural patients in the Carle catchment area (Decatur, Danville, Champaign, rural Coles County), the implantation procedure itself requires a single clinic visit to Urbana. Remote monitoring via the MyCareLink bedside transmitter or the Confirm Rx smartphone app then eliminates the requirement for subsequent in-person device interrogations; all data are available to the cardiologist remotely. The rural patient who drives 60 miles to Urbana for the implantation procedure does not need to return to Urbana for routine device follow-up.

12.2 Margaret’s Story — A Rural Illinois ILR Case

The following scene is drawn from the composite of patients I have cared for at Carle Foundation Hospital. All identifying details are changed.

Margaret is 67 years old and farms 400 acres of soybeans with her husband in Douglas County, Illinois. In November, she has an ischemic stroke that partially resolves; she is left with mild word-finding difficulty. The MRI shows a small cortical infarct in the left MCA territory. No AF is documented on her 5-day hospital telemetry or her 30-day outpatient event monitor. Her echocardiogram shows mild LA enlargement (4.2 cm) and preserved EF. She is started on aspirin.

Her CHA2DS2-VASc score is 5 (female sex, age 67, hypertension, prior stroke). Her cardiologist recommends ILR implantation. Margaret drives to Carle in Urbana for the 20-minute procedure. She receives a Reveal LINQ and a MyCareLink bedside transmitter. The device uploads her data nightly.

At 94 days post-implantation, the Medtronic Carelink portal flags a 43-minute episode of irregular rhythm. The cardiologist reviews the stored ECG: irregular RR intervals with fibrillatory baseline consistent with AF. Margaret is called and started on apixaban. Six months later, she reports no new neurological symptoms.

This case illustrates what the CRYSTAL AF trial documented statistically. The ILR did not prevent Margaret’s first stroke. It identified the cause of that stroke at 94 days post-event, enabling treatment that may prevent the next one.

12.3 SDE Program ILR Workflow

In the SDE Cohort program, patients who meet ILR criteria (cryptogenic stroke, unexplained syncope with high-risk features, suspected paroxysmal AF after negative external monitoring) are referred to the Carle EP lab for consultation. The SDE clinical team coordinates the pre-procedure evaluation (anticoagulation review, infection risk assessment, antibiotic prophylaxis protocol) and the post-procedure remote monitoring setup. Results are reviewed monthly in the SDE clinical rounds; any ILR-detected event that changes management triggers an urgent clinical response within 24 hours.

The goal of ILR monitoring in the SDE framework is not simply to detect arrhythmias; it is to close the loop between detected rhythm and clinical action within the shortest possible time. The CRYSTAL AF trial’s 30% AF detection rate at 3 years means that among the SDE patients with ILR monitoring, approximately 30% will have AF detected during the monitoring period. Each detection event requires a clinical response. The infrastructure to deliver that response (the remote monitoring portal, the clinical team review process, the anticoagulation management pathway) is what converts ILR data from raw rhythm information into clinical benefit.